Ascelia Pharma AB (publ) (ACE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to the webcast for Ascelia Pharma's Q1 report for 2026. On this call we will be making forward looking statements. On today's call we will start with an overview of Ascelia Pharma and recent key events, and then we'll head into the portfolio update before moving to financials and priorities ahead. After the presentation, we will open up for questions. At Ascelia Pharma, we identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. Our company is based in Malmo, Sweden and we are listed on NASDAQ's Defy, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. Our company is based in Malmo, Sweden and we are listed on Nasdaq Stockholm. We have two drugs in our pipeline. OrbiGlambs is a diagnostic drug that is now under FDA review with a PDUFA date of 07/03/2026. We will spend the majority of this call talking about OrbiGlans. Oncrol is a patented tablet formulation of ibreenutrikin with encouraging results in phase one and potential to treat a range of solid tumors. On the progress, of the first quarter this year, we at the European Society for Gastrointestinal and Abdominal Radiology Conference also shortened ESCAR. There will be an oral presentation about Orbeglands by Professor Dominic Geisel from the Charity Hospital in Berlin. Doctor Geisel was an investigator in our phase three study and Charity is one of the largest hospitals in Europe. During the first quarter our previously communicated changes in the management team took place as Anton Hansen started as our Chief Financial Officer and Julie Brogren left Ascelia. After the close of the quarter in April, we made a directed share issue and raised 20,000,000 Swedish kronor before cost, extends our c...